The Global Troponin Market is Anticipated to Witness High Growth Owing to Rising Incidence of Cardiovascular Diseases

 

Global Troponin Market

Troponin is a protein that plays a key role in the contraction of striated muscle. Troponin levels are routinely used in clinical practice as biochemical cardiac markers to aid in the diagnosis and assessment of myocardial infarction and other cardiac conditions. Troponins have a high cardiac specificity which makes it the preferred biomarker over other older biomarkers like CK-MB. Rapid advancements have been made in Troponin assays improving their analytical and diagnostic performance which has fuelled their widespread adoption in cardiac testing across various healthcare settings globally.

The Global Troponin Market is estimated to be valued at US$ 1.38 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the Global Troponin Market Demand are Roche Diagnostics, Abbott Laboratories, Beckman Coulter, Response Biomedical, Vitro, Siemens Healthcare GmbH, Radiometer Medical ApS, bioMérieux SA, Thermo Fisher Scientific, Mitsubishi Chemical Europe, and other prominent players. These players are engaged in new product launches, partnerships and collaborations to expand their market reach globally.

Increasing investments in R&D for developing high sensitivity and accurate Troponin assays present lucrative opportunities for market players. Growing awareness about cardiac health and increasing adoption of troponin testing in emerging economies of Asia Pacific and Latin America provide opportunities for global expansion.

Cardiovascular disease diagnosis rate is on the rise globally owing to aging population and lifestyle changes leading to increased demand for troponin tests. Further advancements are enabling early detection of cardiac injuries and improving clinical outcomes.

Market drivers

Rising geriatric population prone to cardiac issues and growing incidence of coronary artery disease, heart failure and other heart conditions across regions are driving increased adoption of troponin assays. Rapid automation and integration of troponin tests with clinical chemistry analyzers has significantly improved testing efficiency which propels the market growth.

Market restrain - Stringent regulatory approvals delay market entry of new players. Cost of high sensitivity troponin assays limits adoption in low and middle-income regions. Complex reimbursement structure also poses challenges in market expansion.

Segment Analysis

Troponin test market is segmented into high-sensitive troponin, cardiac troponin T, and cardiac troponin I. High-sensitive troponin segment dominates the market and is valued at USD 900 million in 2024. This segment is dominating as it allows detection of troponin in blood even before the onset of symptoms of acute myocardial infarction. It helps in early diagnosis of myocardial injury.

The cardiac troponin T segment holds the second largest share in the global market. It is valued at USD 350 million in 2024. This troponin type is preferred for assessment of myocardial damage and detection of myocardial infarction. The cardiac troponin I segment accounts for around USD 130 million in 2024. It is used for early detection of heart attack as it is released in blood within 4-6 hours after onset of chest pain.

Global Analysis

The North America region dominates the global troponin market with a share of over 40% in 2024. This is attributed to growing geriatric population, rising prevalence of cardiovascular diseases, availability of advanced healthcare facilities, and presence of major market players in the region. Europe is the second largest market due to increasing research on cardiac biomarkers. The Asia Pacific region is expected to witness the fastest growth during the forecast period owing to improving healthcare infrastructure, increasing healthcare spending, and growing awareness about heart diseases.

Get more insights on Global Troponin Market